- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 364 Days
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Preeclampsia With Severe Features
- Interventions
- Cheetah® non-invasive cardiac monitoring system, Standard of care
- Device · Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Iron Deficiency Anemia of Pregnancy
- Interventions
- Ferrous sulfate 325mg, Ferumoxytol
- Dietary Supplement · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Fort Lauderdale, Florida • Maitland, Florida + 2 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 21 more
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- vincristine sulfate, carmustine, melphalan, cyclophosphamide, prednisone, recombinant interferon alfa-2b, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV, Acute HIV Infection
- Interventions
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 33 more
- Conditions
- Arthroplasty, Replacement, Knee
- Interventions
- Depodur, sciatic nerve block
- Drug · Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Neurobehavioral Disinhibition
- Interventions
- Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 54
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Shoulder Arthroplasty, Positive C. Acnes Culture
- Interventions
- Povidone-Iodine, Hydrogen Peroxide, Xperience Antimicrobial Wash, Bacterial Cultures, Shoulder Arthroplasty
- Device · Diagnostic Test · Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
- Interventions
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 161
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
- Conditions
- Pain, Postoperative
- Interventions
- Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
- Drug · Other
- Lead sponsor
- Neumentum, Inc.
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
- Conditions
- Myopia, Progressive
- Interventions
- Atropine Sulfate
- Drug
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- Not listed
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pseudobulbar Affect (PBA)
- Interventions
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Neuroblastoma
- Interventions
- 131I-MIBG, Vincristine, Irinotecan, Vorinostat
- Radiation · Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
- Conditions
- Exercise-Induced Bronchoconstriction (EIB)
- Interventions
- Albuterol Spiromax, Placebo Spiromax
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 6
- States / cities
- San Diego, California • Denver, Colorado • Wheaton, Maryland + 2 more
- Conditions
- Toxic Effect of Organophosphate and Carbamate Insecticides
- Interventions
- Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
- Drug
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Irritation Potential of Topic Agent
- Interventions
- ATx201 Gel 2%, ATx201 Gel 4%, Positive Control, Negative Control, ATx201 Placebo
- Drug
- Lead sponsor
- UNION therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- HIV
- Interventions
- Truvada, Combivir, Trizivir
- Drug
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Environmental Enteric Dysfunction, Zinc Deficiency, Vitamin A Deficiency
- Interventions
- 3 mg zinc sulfate supplement, 0.5 mg of 13C10-retinyl-acetate
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Months to 24 Months
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Migraine, With or Without Aura
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 61 more